The Albumin in Subarachnoid Hemorrhage (ALISAH) multicenter pilot clinical trial: safety and neurologic outcomes. - Wikidata - awgldk - TriplyDB

The Albumin in Subarachnoid Hemorrhage (ALISAH) multicenter pilot clinical trial: safety and neurologic outcomes.

The Albumin in Subarachnoid Hemorrhage (ALISAH) multicenter pilot clinical trial: safety and neurologic outcomes.

http://www.wikidata.org/entity/Q35784963

about

Fluid management of the neurological patient: a concise review Cerebral Vasospasm in Critically III Patients with Aneurysmal Subarachnoid Hemorrhage: Does the Evidence Support the Ever-Growing List of Potential Pharmacotherapy Interventions?The critical care management of poor-grade subarachnoid haemorrhage Docosahexaenoic acid complexed to human albumin in experimental stroke: neuroprotective efficacy with a wide therapeutic window Clinical trials in cardiac arrest and subarachnoid hemorrhage: lessons from the past and ideas for the future.Medical Management of Cerebral Vasospasm following Aneurysmal Subarachnoid Hemorrhage: A Review of Current and Emerging Therapeutic Interventions.Delayed cerebral ischaemia prevention and treatment after aneurysmal subarachnoid haemorrhage: a systematic review Neuroprotection in stroke: past, present, and future.Delayed neurological deterioration after subarachnoid haemorrhage.Current management of delayed cerebral ischemia: update from results of recent clinical trials.The network topology of aneurysmal subarachnoid haemorrhage.Prehospital stroke care: telemedicine, thrombolysis and neuroprotection.Early Hypoalbuminemia is an Independent Predictor of Mortality in Aneurysmal Subarachnoid Hemorrhage.Proteomic signatures of serum albumin-bound proteins from stroke patients with and without endovascular closure of PFO are significantly different and suggest a novel mechanism for cholesterol efflux Bayesian dose selection design for a binary outcome using restricted response adaptive randomization.Adrenomedullin concentration in the cerebrospinal fluid is related to appetite loss and delayed ischemic neurological deficits after subarachnoid hemorrhage.Association of early post-procedure hemodynamic management with the outcomes of subarachnoid hemorrhage patients.Albumin-Induced Neuroprotection in Focal Cerebral Ischemia in the ALIAS Trial: Does Severity, Mechanism, and Time of Infusion Matter?Novel method for rapid reversal of drug toxicity: a case report.Aneurysmal Subarachnoid Hemorrhage.Human albumin administration in subarachnoid hemorrhage: results of an international survey.Neuroinflammation as a Target for Intervention in Subarachnoid Hemorrhage.

P2860

Q26744778-579DDEDA-A91E-4CDE-B096-F301FDD374FA Q34612924-670DBE46-54F8-4845-B005-3B36CEEAE17D Q36493587-19B14437-C7BD-4893-ABFE-D9C0B2592053 Q36517694-6174C2AD-E4BD-48F0-B3DA-C4A4F00F07CF Q36711857-56423587-610D-4178-B862-0BA88DA9FCD3 Q36831190-1E06BB8E-AE01-495D-826C-27EF44FF2E68 Q37019652-11F2F5A9-B491-4280-A7E7-9BA173DC7FA8 Q37571562-2034A359-F944-420A-A4D7-E0C481759944 Q38169976-5E468A2E-0673-43DC-ACE6-D48B66C4A14B Q38171354-1C78DB36-3E22-4E42-92C8-92CEB918EF61 Q38422787-13D670BC-D775-4B9E-B370-52F818E694C7 Q38537388-196349C0-33B3-4B1F-9AA2-7F3F8DE26561 Q39964606-613EC42D-9C3A-42A1-BD5E-CF496B767593 Q41440445-D4ECEE3A-707C-477C-862F-93425DAE1EB3 Q41465675-3C820DDB-2BEA-4027-B194-D2BAB364EF81 Q44491923-065D9AA0-3B77-4E40-86AC-8D737FFA3DB4 Q45158620-62589B49-94FA-451F-9F32-6C147DBDD731 Q50703442-0DDBAD1D-C010-440B-A2CC-F4A7BADFA867 Q51063951-DCE52F23-561F-44E2-AB76-6A8F2782468E Q53083421-7C883ACF-80EF-4C96-B68F-E41B5EE238DF Q53097470-96897B20-0938-40FE-820A-2D612E8F6EA3 Q55024490-6EBE96B0-809D-4872-AE4F-D312C02E457C

P2860

The Albumin in Subarachnoid Hemorrhage (ALISAH) multicenter pilot clinical trial: safety and neurologic outcomes.

http://www.wikidata.org/entity/Q35784963

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

The Albumin in Subarachnoid He ...... afety and neurologic outcomes.

@ast

The Albumin in Subarachnoid He ...... afety and neurologic outcomes.

@en

type

label

The Albumin in Subarachnoid He ...... afety and neurologic outcomes.

@ast

The Albumin in Subarachnoid He ...... afety and neurologic outcomes.

@en

prefLabel

The Albumin in Subarachnoid He ...... afety and neurologic outcomes.

@ast

The Albumin in Subarachnoid He ...... afety and neurologic outcomes.

@en

P1433

Q35784963-2982FBC3-193D-4EC7-B8F1-6BCF61AC5F8D

P1476

Q35784963-32D3D175-46BA-45CC-BBCA-547FA6BD7DDE

P2093

Q35784963-17B45107-C6C6-4FBE-8C20-06E81873AD2F

Q35784963-22329A4F-1FB3-4970-B02D-1282FEE40959

Q35784963-39A042CD-ECA3-4075-9C49-89877A84DA4E

Q35784963-477E8552-FDF2-420D-9C4E-3B045C81701A

Q35784963-65F9CB59-54E4-45BB-9464-4531FDD9E94B

Q35784963-6792892E-AA50-4ED6-A0C4-BCEB78301AAA

Q35784963-80A6008F-8566-400E-A2BA-C1BE75AFBAA7

Q35784963-8D13A684-36A2-4ED4-BA53-2A79D2537B76

P2860

Q35784963-0366617B-C1CC-4C84-A162-9ACDDD65EC1E

Q35784963-1AA39412-8CE7-4FF8-A922-220AA2896831

Q35784963-22E2C359-9BC9-474C-8AC6-C88FAF26BA42

Q35784963-2CC474D8-2D85-46EC-AF8F-6B58815831F8

Q35784963-4B801F00-095B-4BD6-BCEE-EDCE0CBC4A3F

Q35784963-7520D0F9-3BEA-4260-8460-B4A340875950

Q35784963-82CDED80-D43D-4C51-982A-44CEDA15C438

Q35784963-882DB183-6D36-4887-9C6B-821111DBFFB4

Q35784963-889F7214-60E3-4BC3-A72A-CE52B7DCB130

Q35784963-8C20FF88-54E9-4138-946A-9E5E63F63E50

P304

Q35784963-53438F95-E361-4783-BDCA-04CC4E6DF0CC

P31

Q35784963-78FAD820-8379-49B5-9F7B-B1B564B3DAC9

P356

Q35784963-1D12AC20-3CAB-49CA-834B-CE8477CB4653

P407

Q35784963-5ECE9C4E-7983-4ABF-B66B-FC07F13F0EA9

P433

Q35784963-667364B1-6D88-451D-A794-C8CE1C5871A6

P478

Q35784963-69B2BC92-9852-46C2-AC87-C2E2324B9CDE

P50

Q35784963-BC4FDD48-788D-4081-B06D-676800AD9B02

P577

Q35784963-4FD8169C-1D60-4729-8BCF-7ADA643AF968

P698

Q35784963-505F80C4-921A-4D23-BCE3-B0785C2F7A76

P921

Q35784963-EA8FEDD9-662D-4907-B2AB-DB2ACBDFB800

P932

Q35784963-9CA0C347-20C8-439C-BACC-055A72ACB17E

P356

STROKEAHA.111.633958

P1433

P1476

The Albumin in Subarachnoid He ...... afety and neurologic outcomes.

@en

P2093

ALISAH Investigators

http://www.w3.org/2001/XMLSchema#string

Catherine Dillon

http://www.w3.org/2001/XMLSchema#string

Eric M Bershad

http://www.w3.org/2001/XMLSchema#string

Eusebia Calvillo

http://www.w3.org/2001/XMLSchema#string

John Wong

http://www.w3.org/2001/XMLSchema#string

Jose I Suarez

http://www.w3.org/2001/XMLSchema#string

R Loch Macdonald

http://www.w3.org/2001/XMLSchema#string

Renee H Martin

http://www.w3.org/2001/XMLSchema#string

P2860

A randomized controlled trial of high-dose intravenous nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study.

Diffusion-weighted magnetic resonance imaging confirms marked neuroprotective efficacy of albumin therapy in focal cerebral ischemia.

Noninvasive ventilation in acute cardiogenic pulmonary edema: systematic review and meta-analysis.

NO forms an adduct with serum albumin that has endothelium-derived relaxing factor-like properties.

Calcium antagonists for aneurysmal subarachnoid haemorrhage.

Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association.

The Albumin in Acute Stroke Part 1 Trial: an exploratory efficacy analysis

Specific binding sites for albumin restricted to plasmalemmal vesicles of continuous capillary endothelium: receptor-mediated transcytosis

Preferential interaction of albumin-binding proteins, gp30 and gp18, with conformationally modified albumins. Presence in many cells and tissues with a possible role in catabolism.

gp60 is an albumin-binding glycoprotein expressed by continuous endothelium involved in albumin transcytosis.

P304

683-690

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/STROKEAHA.111.633958

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

43

http://www.w3.org/2001/XMLSchema#string

P50

Robert Harbaugh

P577

2012-01-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22267829

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

3288646

http://www.w3.org/2001/XMLSchema#string